GLP-1 Peptide Atlas, by Delfa

WithdrawnPhase 3

Albiglutide Versus Placebo Added-on to Basal-Bolus Insulin Therapy in Subjects With Type 2 Diabetes Mellitus

Study GLP111892: Albiglutide Versus Placebo as Add-on to Intensified Basal-Bolus Insulin Therapy in Subjects With Type 2 Diabetes Mellitus

Lead sponsor

GlaxoSmithKline

Asset

Albiglutide

Subcutaneous · GLP-1 agonist

Listed sites

Recruiting sites

—

Enrollment

—

actual

Study population

Type 2 diabetes

Key I/E criteria

•BMI ≤40•HbA1c 7.5-10%

Primary endpoints

•Documented hypoglycemia (Severe hypoglycemia, Documented hypoglycemia)•HbA1c, change

Identifiers

Registered as

NCT IDNCT02229240

Org study ID111892

Timeline

Milestones

Study first posted2014-09-01estimated

Last update posted2016-01-11estimated

Study start2015-08 (month precision)

Primary completion2015-12estimated (month precision)

Study completion2015-12estimated (month precision)

Assets

Investigational agents

Albiglutide

Study populations

Who this study enrolls

Type 2 diabetes

Eligibility

Who can enroll

Minimum age18 Years

SexAll

Healthy volunteersNot accepted

Inclusion criteria

•Male or female, 18 years of age or older (inclusive at the time of Screening) with T2DM

•HbA1c >=7.5% and <=10.0% at Screening.

•Currently treated with a basal-bolus insulin regimen (with or without metformin) for at least 3 months before Screening. The subject must be taking the following: Basal insulin (1 or 2 daily injections of neutral protamine Hagedorn insulin, insulin glargine, insulin detemir, or insulin degludec) AND Bolus insulin (at least 2 injections of regular insulin, insulin glulisine, insulin aspart, or insulin lispro); In addition, the total daily dose of insulin must be <=150 units; If taking metformin, a stable dose for at least 8 weeks before Screening. Note: Subject should not have received any other antidiabetic medication within 30 days before Screening (e.g., glucagon-like peptide-1 receptor [GLP-1R] agonist, dipeptidyl peptidase-IV inhibitor, sulfonylurea, or thiazolidinedione). Subjects receiving commercially available premixed basal and prandial insulin are not eligible for this study.

•Body mass index <=40 kilogram (kg) per squaremeter (m^2)

•Thyroid-stimulating hormone (TSH) level is normal or clinically euthyroid as demonstrated by further thyroid tests (e.g., free T4 )

•Female subjects of childbearing potential (i.e., not surgically sterile and/or not postmenopausal) must be practicing adequate contraception (as defined in the protocol) for the duration of participation in the study including the 4-week Posttreatment Follow-up Period.

•Willing and able to comply with all study procedures including intensive insulin administration and performance of frequent SMBG profiles according to the protocol

•Able and willing to provide written informed consent

Exclusion criteria

•Type 1 diabetes mellitus

•History of cancer that has not been in full remission for at least 3 years before Screening. (A history of squamous cell or basal cell carcinoma of the skin or treated cervical intra-epithelial neoplasia I or II is allowed)

•Personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2

•Current symptomatic biliary disease or history of acute or chronic pancreatitis

•Severe gastroparesis, i.e., requiring regular therapy within 6 months before Screening

•History of significant GI surgery that in the opinion of the investigator is likely to significantly affect upper GI or pancreatic function (e.g., gastric bypass and banding, antrectomy, Roux en Y bypass, gastric vagotomy, small bowel resection, or surgeries thought to significantly affect upper GI function)

•History of severe hypoglycemia unawareness

•Diabetic complications (e.g., active proliferative retinopathy or severe diabetic neuropathy) or any other clinically significant abnormality (including a psychiatric disorder) that, in the opinion of the investigator, may pose additional risk in administering the investigational product

•Clinically significant cardiovascular and/or cerebrovascular disease within 3 months before Screening including, but not limited to, the following: Stroke or transient ischemic attack; Acute coronary syndrome (myocardial infarction [MI] or unstable angina not responsive to nitroglycerin); Cardiac surgery or percutaneous coronary procedure; Current or history of heart failure (New York Heart Association class III or IV)

•Alanine aminotransferase (ALT) >2.5 × upper limit of normal (ULN) or bilirubin >1.5 × ULN (isolated bilirubin >1.5 × ULN is acceptable if bilirubin is fractionated and direct bilirubin <35%)

•Unstable liver disease (as defined by the presence of ascites, encephalopathy, coagulopathy, hypoalbuminemia, esophageal or gastric varices, or persistent jaundice), cirrhosis, known biliary abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones). (Chronic stable hepatitis B and C are acceptable if subject otherwise meets entry criteria and is not on active antiviral treatment [e.g., presence of hepatitis B surface antigen or positive hepatitis C test result within 3 months of Screening])

•Hemoglobin <11 g/dL (<110 gram per liter [g/L]) for male subjects and <10 g/dL (<100 g/L) for female subjects at Screening

•Estimated glomerular filtration rate (eGFR) <=30 mL/minute/1.73 m^2 (calculated using the Modification of Diet in Renal Disease [MDRD] formula) at Screening. Note: As the use of metformin in subjects with varying degrees of renal function may differ from country to country, use of metformin should be in accordance with the metformin product label within the participating country.

•Fasting triglyceride level >750 mg/dL at Screening

•Hemoglobinopathy that may affect proper interpretation of HbA1c

•Known allergy to albiglutide or any product components (including yeast and human albumin), any other GLP-1 analogue, insulin, or other study medication's excipients OR other contraindications (per the prescribing information) for the use of potential study medications (e.g., basal-bolus insulin)

•Use of oral or systemically injected glucocorticoids within the 3 months before randomization or high likelihood of a requirement for prolonged treatment (>1 week) in the 6 months following randomization. However, short courses of oral steroids (single dose or multiple doses for up to 7 days) may be permitted provided these cases are discussed with the medical monitor. Inhaled, intra-articular, epidural, and topical corticosteroids are allowed

•Female subject is pregnant (confirmed by laboratory testing) or lactating

•Receipt of any investigational drug within the 30 days or 5 half-lives, whichever is longer, before Screening, a history of receipt of an investigational antidiabetic drug within the 3 months before randomization, or receipt of albiglutide in previous studies

•Subject that, in the opinion of the investigator, will not benefit from participating in a treat to target study aimed at achieving HbA1c of 7.0%

Endpoints (13)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Glycemic / diabetes

Safety / tolerability / PK

Weight & body composition

1 endpoint

Secondary/protocol endpoint

Change from baseline in body weight at Week 26 and over time

Time frame:Up to Week 26

Body weight, absolute change (kg)

change from baseline, improvement

Glycemic / diabetes

8 endpoints

Primary/protocol endpoint

Change from baseline in glycosylated hemoglobin (HbA1c) at Week 26

Time frame:Week 26

HbA1c, change

change from baseline, improvement

LOINC 4548-4

Secondary/protocol endpoint

Total daily insulin dose, basal insulin dose and bolus insulin dose at Week 26 and over time

Time frame:Up to Week 26

descriptive

Secondary/protocol endpoint

HbA1c change from baseline in over time

Time frame:Up to Week 26

HbA1c, change

change from baseline, improvement

LOINC 4548-4

Secondary/protocol endpoint

Fasting plasma glucose (FPG) change from Baseline at Week 26 and over time

Time frame:Up to Week 26

Fasting glucose, change

change from baseline, improvement

LOINC 1558-6

Secondary/protocol endpoint

Proportion of subjects achieving a HbA1c <7.0% and < 6.5% at Week 26 and over time

Time frame:Up to Week 26

HbA1c <7.0% achievement

threshold achievement, improvement

LOINC 4548-4

Secondary/protocol endpoint

Percentage of subjects achieving HbA1c <7.0% without weight gain after 26 weeks of treatment

Time frame:Up to Week 26

HbA1c <7.0% achievement

threshold achievement, improvement

LOINC 4548-4

Secondary/protocol endpoint

Percentage of subjects achieving HbA1c <7.0% without severe or documented symptomatic hypoglycemia after 26 weeks of treatment

Time frame:Up to Week 26

HbA1c <7.0% achievement

threshold achievement, improvement

LOINC 4548-4

Secondary/protocol endpoint

Percentage of subjects achieving HbA1c <7.0% without weight gain and without severe or documented hypoglycemia after 26 weeks of treatment

Time frame:Up to Week 26

HbA1c <7.0% achievement

threshold achievement, improvement

componentsHbA1c <7.0% achievement, Body weight, absolute change (kg), Severe hypoglycemia, Documented hypoglycemia

LOINC 4548-4

Safety / tolerability / PK

4 endpoints

Primary/protocol endpoint

Percentage of subjects with severe or documented symptomatic hypoglycemia through Week 26

Time frame:Up to Week 26

Documented hypoglycemia

threshold achievement, event

componentsSevere hypoglycemia, Documented hypoglycemia

Secondary/protocol endpoint

Number of subjects with non-serious adverse events (AE), serious adverse events (SAE), and AEs and SAEs leading to discontinuation

Time frame:Up to Week 30

Serious AEs (any)

descriptive, event

componentsTreatment-emergent AEs (any), Serious AEs (any), Discontinuation due to AE

Secondary/protocol endpoint

Incidence of hypoglycemic events

Time frame:Up to Week 30

event count, event

Secondary/protocol endpoint

Assessment of clinical laboratory tests, lipids, vital signs, ECGs and physical examinations

Time frame:Up to Week 30

descriptive

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2

Snapshot dateJuly 1, 2026

Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)

Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.